Dhruti P Chen1, Elizabeth A McInnis2, Eveline Y Wu3, Katherine G Stember2,4, Susan L Hogan2, Yichun Hu2, Candace D Henderson2, Lauren N Blazek2, Simon Mallal5, Edita Karosiene6, Bjoern Peters6, John Sidney6, Eddie A James7, William W Kwok8, J Charles Jennette2,3, Dominic J Ciavatta2,8, Ronald J Falk2,3, Meghan E Free2. 1. Department of Medicine, University of North Carolina Kidney Center, Chapel Hill, North Carolina dhruti_chen@med.unc.edu. 2. Department of Medicine, University of North Carolina Kidney Center, Chapel Hill, North Carolina. 3. Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina. 4. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina. 5. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California. 7. Translational Research Program, Benaroya Research Institute, Seattle, Washington. 8. Department of Genetics, University of North Carolina, Chapel Hill, North Carolina.
Abstract
BACKGROUND: PR3-ANCA vasculitis has a genetic association with HLA-DPB1. We explored immunologic and clinical features related to the interaction of HLA-DPB1*04:01 with a strongly binding PR3 peptide epitope (PR3225-239). METHODS: Patients with ANCA vasculitis with active disease and disease in remission were followed longitudinally. Peripheral blood mononuclear cells from patients and healthy controls with HLA-DPB1*04:01 were tested for HLA-DPB1*04:01 expression and interaction with a PR3 peptide identified via in silico and in vitro assays. Tetramers (HLA/peptide multimers) identified autoreactive T cells in vitro. RESULTS: The HLA-DPB1*04:01 genotype was associated with risk of relapse in PR3-ANCA (HR for relapse 2.06; 95% CI, 1.01 to 4.20) but not in myeloperoxidase (MPO)-ANCA or the combined cohort. In silico predictions of HLA and PR3 peptide interactions demonstrated strong affinity between ATRLFPDFFTRVALY (PR3225-239) and HLA-DPB1*04:01 that was confirmed by in vitro competitive binding studies. The interaction was tested in ex vivo flow cytometry studies of labeled peptide and HLA-DPB1*04:01-expressing cells. We demonstrated PR3225-239 specific autoreactive T cells using synthetic HLA multimers (tetramers). Patients in long-term remission off therapy had autoantigenic peptide and HLA interaction comparable to that of healthy volunteers. CONCLUSIONS: The risk allele HLA-DPB1*04:01 has been associated with PR3-ANCA, but its immunopathologic role was unclear. These studies demonstrate that HLA-DPB1*04:01 and PR3225-239 initiate an immune response. Autoreactive T cells specifically recognized PR3225-239 presented by HLA-DPB1*04:01. Although larger studies should validate these findings, the pathobiology may explain the observed increased risk of relapse in our cohort. Moreover, lack of HLA and autoantigen interaction observed during long-term remission signals immunologic nonresponsiveness.
BACKGROUND: PR3-ANCA vasculitis has a genetic association with HLA-DPB1. We explored immunologic and clinical features related to the interaction of HLA-DPB1*04:01 with a strongly binding PR3 peptide epitope (PR3225-239). METHODS: Patients with ANCA vasculitis with active disease and disease in remission were followed longitudinally. Peripheral blood mononuclear cells from patients and healthy controls with HLA-DPB1*04:01 were tested for HLA-DPB1*04:01 expression and interaction with a PR3 peptide identified via in silico and in vitro assays. Tetramers (HLA/peptide multimers) identified autoreactive T cells in vitro. RESULTS: The HLA-DPB1*04:01 genotype was associated with risk of relapse in PR3-ANCA (HR for relapse 2.06; 95% CI, 1.01 to 4.20) but not in myeloperoxidase (MPO)-ANCA or the combined cohort. In silico predictions of HLA and PR3 peptide interactions demonstrated strong affinity between ATRLFPDFFTRVALY (PR3225-239) and HLA-DPB1*04:01 that was confirmed by in vitro competitive binding studies. The interaction was tested in ex vivo flow cytometry studies of labeled peptide and HLA-DPB1*04:01-expressing cells. We demonstrated PR3225-239 specific autoreactive T cells using synthetic HLA multimers (tetramers). Patients in long-term remission off therapy had autoantigenic peptide and HLA interaction comparable to that of healthy volunteers. CONCLUSIONS: The risk allele HLA-DPB1*04:01 has been associated with PR3-ANCA, but its immunopathologic role was unclear. These studies demonstrate that HLA-DPB1*04:01 and PR3225-239 initiate an immune response. Autoreactive T cells specifically recognized PR3225-239 presented by HLA-DPB1*04:01. Although larger studies should validate these findings, the pathobiology may explain the observed increased risk of relapse in our cohort. Moreover, lack of HLA and autoantigen interaction observed during long-term remission signals immunologic nonresponsiveness.
Authors: Ronald J Falk; Wolfgang L Gross; Loïc Guillevin; Gary Hoffman; David R W Jayne; J Charles Jennette; Cees G M Kallenberg; Raashid Luqmani; Alfred D Mahr; Eric L Matteson; Peter A Merkel; Ulrich Specks; Richard Watts Journal: Ann Rheum Dis Date: 2011-04 Impact factor: 19.103
Authors: Yali Cao; John L Schmitz; Jiajin Yang; Susan L Hogan; Donna Bunch; Yichun Hu; Caroline E Jennette; Elisabeth A Berg; Frank C Arnett; J Charles Jennette; Ronald J Falk; Gloria A Preston Journal: J Am Soc Nephrol Date: 2011-05-26 Impact factor: 10.121
Authors: Susan L Hogan; Ronald J Falk; Hyunsook Chin; Jianwen Cai; Caroline E Jennette; J Charles Jennette; Patrick H Nachman Journal: Ann Intern Med Date: 2005-11-01 Impact factor: 25.391
Authors: Paul A Lyons; Tim F Rayner; Sapna Trivedi; Julia U Holle; Richard A Watts; David R W Jayne; Bo Baslund; Paul Brenchley; Annette Bruchfeld; Afzal N Chaudhry; Jan Willem Cohen Tervaert; Panos Deloukas; Conleth Feighery; Wolfgang L Gross; Loic Guillevin; Iva Gunnarsson; Lorraine Harper; Zdenka Hrušková; Mark A Little; Davide Martorana; Thomas Neumann; Sophie Ohlsson; Sandosh Padmanabhan; Charles D Pusey; Alan D Salama; Jan-Stephan F Sanders; Caroline O Savage; Mårten Segelmark; Coen A Stegeman; Vladimir Tesař; Augusto Vaglio; Stefan Wieczorek; Benjamin Wilde; Jochen Zwerina; Andrew J Rees; David G Clayton; Kenneth G C Smith Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts Journal: Arthritis Rheum Date: 2013-01
Authors: David Massicotte-Azarniouch; Carolina A Herrera; J Charles Jennette; Ronald J Falk; Meghan E Free Journal: Semin Immunopathol Date: 2022-03-07 Impact factor: 11.759